Plasmatic free light chains in polycystic ovary syndrome

References

• Shorakae S, Teede H, de Courten B, et al. The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome. Semin Reprod Med. 2015;33:257–269.
   PubMed Web of Science ®Google Scholar
• Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol. 2007;192:585–594.
   PubMed Web of Science ®Google Scholar
• Ebejer K, Calleja-Agius J. The role of cytokines in polycystic ovarian syndrome. Gynecol Endocrinol. 2013;29:536–540.
   PubMed Web of Science ®Google Scholar
• Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Polycystic Ovary Syndr Nov Insights Causes Ther. 2012;40:40–50.
   Google Scholar
• Mannerås-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96:304–311.
   PubMed Web of Science ®Google Scholar
• Alanbay I, Ercan CM, Sakinci M, et al. A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity? Arch Gynecol Obstet. 2012;286:1065–1071.
   PubMed Web of Science ®Google Scholar
• Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016:1.
   Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:1048–1058.e1–2.
   Web of Science ®Google Scholar
• Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol. 2010;26:281–296.
   PubMed Web of Science ®Google Scholar
• Deligeoroglou E, Vrachnis N, Athanasopoulos N, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol. 2012;28:974–978.
   PubMed Web of Science ®Google Scholar
• Basile U, Gulli F, Gragnani L, et al. Free light chains: eclectic multipurpose biomarker. J Immunol Methods. 2017;451:11–19.
   PubMed Web of Science ®Google Scholar
• Boivin D, Provençal M, Gendron S, et al. Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. Arch Biochem Biophys. 2004;431:197–206.
   PubMed Web of Science ®Google Scholar
• Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;163:4590–4596.
   PubMed Web of Science ®Google Scholar
• Van Der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol. 2006;533:319–326.
   PubMed Web of Science ®Google Scholar
• Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol. 2003;24:181–185.
   PubMed Web of Science ®Google Scholar
• Cohen G, Rudnicki M, Deicher R, et al. Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. Eur J Clin Invest. 2003;33:669–676.
   PubMed Web of Science ®Google Scholar
• Sengul S, Zwizinski C, Simon EE, et al. Endocytosis of light chains induces cytokines through activation of NF-кB in human proximal tubule cells. Kidney Int. 2002;62:1977–1988.
   PubMed Web of Science ®Google Scholar
• Esparvarinha M, Nickho H, Mohammadi H, et al. The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. Biomed Pharmacother. 2017;91:632–644.
   PubMed Web of Science ®Google Scholar
• Basile U, Bruno C, Napodano C, et al. Plasmatic free light chains as inflammatory marker in insulin resistance: comparison of metabolic syndrome with adult growth hormone deficiency. BioFactors. 2018;44:480–484.
   PubMed Web of Science ®Google Scholar
• Deepika MLN, Nalini S, Maruthi G, et al. Analysis of oxidative stress status through MN test and serum MDA levels in PCOS women. Pakistan J Biol Sci. 2014;17:574–577.
   PubMedGoogle Scholar
• Kaya C, Erkan AF, Cengiz SD, et al. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril. 2009;92:1372–1377.
   Web of Science ®Google Scholar
• Di Segni C, Silvestrini A, Fato R, et al. Plasmatic and intracellular markers of oxidative stress in normal weight and obese patients with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2017;125:506–513.
   PubMed Web of Science ®Google Scholar
• González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77:300–305.
   PubMed Web of Science ®Google Scholar
• Desjardins L, Liabeuf S, Lenglet A, et al. Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins (Basel). 2013;5:2058–2073.
   PubMed Web of Science ®Google Scholar
• Associations of serum free light chains (FLCs) with the risks of end-stage renal disease (ESRD) and of death in chronic kidney disease. Abstract presented at: American Society of Nephrology Renal Week; 2009 Oct 27 - Nov 1; San Diego, CA, USA.
   Google Scholar
• Hopper JE, Golbus J, Meyer C, et al. Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol. 2000;20:123–137.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Sequeira W, Kokebie R, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res. 2011;63:891–898.
   PubMed Web of Science ®Google Scholar
• Hassan-Smith G, Durant L, Tsentemeidou A, et al. High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol. 2014;276:175–179.
   PubMed Web of Science ®Google Scholar
• Ramsden DB. Multiple sclerosis: assay of free immunoglobulin light chains. Ann Clin Biochem. 2017;54:5–13.
   PubMed Web of Science ®Google Scholar
• Terrier B, Sène D, Saadoun D, et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis. 2008;68:89–93.
   PubMed Web of Science ®Google Scholar
• Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28:773–779.
   PubMed Web of Science ®Google Scholar
• Powe DG, Groot Kormelink T, Sisson M, et al. Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. J Allergy Clin Immunol. 2010;125(1):139–45.e1-3.
   PubMed Web of Science ®Google Scholar